• Profile
Close

Impact of COVID-19 pandemic on uveitis patients receiving immunomodulatory and biological therapies (COPE STUDY)

British Journal of Ophthalmology Oct 07, 2020

Agarwal AK, Sudharshan S, Mahendradas P, et al. - Researchers conducted this national multicentric prospective case series to assess the change in the ongoing immunomodulatory (IMT) and biological therapies among patients with non-infectious uveitis (NIU), and determine the number of uveitis relapses during the COVID-19 pandemic. Data of patients with NIU receiving corticosteroids, systemic IMT and/or biological agents have been analyzed. The sample consisted of 176 patients (284 eyes) with NIU (mean age: 33±17.1 years; males: 68). In total, 121 eyes (90 patients) were deemed to have active NIU. Uveitis specialists may tend to reduce the ongoing systemic IMT during the ongoing COVID-19 pandemic, or prefer less aggressive NIU treatment strategies. Such individuals may be at high risk of relapse of uveitis.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay